Delix Therapeutics Raises $100M for Zalsupindole Trials

Two hours of observation after a dose is a substantial piece of a patient's day. Delix Therapeutics is developing an oral depression medicine intended to change the practical demands around treatment, using molecular design to pursue neuroplasticity without hallucinations.

The Bedford, Massachusetts neuroscience company announced an oversubscribed $100M Series C on November 9, 2026, co-led by Johnson & Johnson's venture organization JJDC and SV Health Investors' Dementia Discovery Fund. The financing supports Phase IIb development of zalsupindole for recurrent major depressive disorder and the company's wider neuroplastogen pipeline.

Delix expects a placebo-controlled Phase II study to begin in the first half of 2027. For investors and care providers, the proposition combines a clinical question about sustained antidepressant benefit with an operating question about how patients could receive a future treatment; zalsupindole remains investigational.

Why the treatment setting belongs in the investment story

A clinic can become part of a medicine's delivery system. The current SPRAVATO prescribing label requires administration under professional supervision and monitoring for at least 2 hours after a dose because of identified risks. That creates work around the treatment itself: observation, clinical capacity and time away from the rest of a patient's life.

Delix's approach begins earlier, in the chemistry. The company wants medicines that retain neuroplasticity-promoting activity while avoiding the hallucinatory, dissociative and sedative experiences that can complicate administration. An oral candidate intended for home use gives that scientific project a practical destination, although its eventual prescribing conditions will depend on evidence and regulatory review.

The commercial implication is a possibility worth examining rather than a demonstrated saving. A future treatment that requires fewer supervised hours could put different demands on a care organization, but this financing supplies no head-to-head comparison, reimbursement agreement or approved home-use pathway. For providers evaluating the category, mental-health care operations make the treatment routine worth examining as carefully as the molecule.

What Delix is asking zalsupindole to do

Neuroplasticity describes the nervous system's capacity to change its connections. Delix is developing small molecules intended to promote structural and functional changes in neural circuits, with the aim of translating that biology into treatments for psychiatric and neurological conditions. Zalsupindole, also called DLX001, is the lead clinical example in the current financing announcement.

The research history explains why the company is interested in modifying psychedelic-inspired compounds. Co-founder David E. Olson, Delix's chief innovation officer, studied how these substances affect neuronal structure through his academic work at UC Davis. Delix was co-founded with Nick Haft, bringing a company-building and investment relationship around the scientific work.

The company's research-publication record spans several years of neuroplasticity and medicinal-chemistry work. That history helps explain the platform's origin, while human therapeutic benefit still has to be established for each candidate and indication. Evidence of neuronal changes in an experimental model and improvement in a person's depression are different observations that a development program has to connect.

Delix reports a discovery inventory of more than 1,500 compounds across more than 10 chemical scaffolds on its pipeline page. That is a source of research options, not a count of medicines ready for clinical use. Selecting which of those options deserves clinical resources is a substantial part of running the company.

What the clinical evidence supports so far

Delix reports that adults with recurrent major depressive disorder in its Phase Ib study had an approximately 50% mean reduction in Montgomery-Åsberg Depression Rating Scale scores at Day 8, after 1 week of treatment. The company says the improvement persisted through Day 36, 4 weeks after the final dose. These are preliminary issuer-reported findings, rather than evidence that half the patients achieved remission or that the drug outperformed placebo.

The company also reports observations across more than 120 participants studied to date, with no hallucinatory, dissociative or psychotomimetic effects observed. That aggregate should be read separately from the depression cohort. It describes the company's accumulated early experience, while a larger controlled study can examine benefits and risks under a more demanding design.

The planned Phase II program matters because the development question becomes more specific. Patients' outcomes must be interpreted alongside a comparison group, dosing choices and the persistence of any improvement. Clinical planning now sits directly beside the ambition to make treatment less disruptive, giving the financing a defined piece of work to support.

Who is financing the next stage

JJDC and the Dementia Discovery Fund join a syndicate with existing Delix investors RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures and Bail Capital. New investors named in the release include Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital and YK Bioventures. The company also announced board appointments for SV Health Investors partner Christian Jung and a JJDC representative.

CEO Mark Rus brings experience from Shire's neuroscience business and Atlas Venture to this phase of development. The leadership assignment spans the lead trial and a broader set of research programs, making the allocation of scientific and operational attention consequential alongside the allocation of capital.

Delix's earlier $70M Series A, announced in September 2021, supported the move toward initial clinical development. The new financing follows that progression into a planned controlled depression study while also funding additional candidates and neurodegeneration work. The current primary announcement leaves valuation and a comprehensive lifetime financing total undisclosed.

DDF's participation makes the wider pipeline especially relevant to understanding the transaction. The lead development milestone concerns depression, while the funded research also reaches toward neurological and neurodegenerative conditions. Delix will be making those program decisions as its clinical team prepares the placebo-controlled study, carrying an ambition for take-home treatment into the details of how zalsupindole is evaluated.